Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy

Jennifer M. Wickens, Hashem O. Alsaab, Prashant Kesharwani, Ketki Bhise, Mohd Cairul Iqbal Mohd Amin, Rakesh Kumar Tekade, Umesh Gupta, Arun K. Iyer

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The cluster-determinant 44 (CD44) receptor has a high affinity for hyaluronic acid (HA) binding and is a desirable receptor for active targeting based on its overexpression in cancer cells compared with normal body cells. The nanocarrier affinity can be increased by conjugating drug-loaded carriers with HA, allowing enhanced cancer cell uptake via the HA-CD44 receptor-mediated endocytosis pathway. In this review, we discuss recent advances in HA-based nanocarriers and micelles for cancer therapy. In vitro and in vivo experiments have repeatedly indicated HA-based nanocarriers to be a target-specific drug and gene delivery platform with great promise for future applications in clinical cancer therapy. Hyaluronic acid (HA) has potential as a unique targeting ligand for treating multiple types of tumor overexperssing cluster-determinant 44 (CD44) receptors, including stem-like cancer cells (SLCC). Here, we discuss the innovative approaches of HA-decorated nanocarriers developed by researchers for delivering drugs and genes to cancer cells.

Original languageEnglish
JournalDrug Discovery Today
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Hyaluronic Acid
Neoplasms
Therapeutics
Drug Carriers
Neoplastic Stem Cells
Neoplasm Genes
Micelles
Endocytosis
Pharmaceutical Preparations
Research Personnel
Ligands
Genes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Wickens, J. M., Alsaab, H. O., Kesharwani, P., Bhise, K., Mohd Amin, M. C. I., Tekade, R. K., ... Iyer, A. K. (Accepted/In press). Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2016.12.009

Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. / Wickens, Jennifer M.; Alsaab, Hashem O.; Kesharwani, Prashant; Bhise, Ketki; Mohd Amin, Mohd Cairul Iqbal; Tekade, Rakesh Kumar; Gupta, Umesh; Iyer, Arun K.

In: Drug Discovery Today, 2016.

Research output: Contribution to journalArticle

Wickens, Jennifer M. ; Alsaab, Hashem O. ; Kesharwani, Prashant ; Bhise, Ketki ; Mohd Amin, Mohd Cairul Iqbal ; Tekade, Rakesh Kumar ; Gupta, Umesh ; Iyer, Arun K. / Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. In: Drug Discovery Today. 2016.
@article{e422827ddf2b4106a5c816a39d4e5942,
title = "Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy",
abstract = "The cluster-determinant 44 (CD44) receptor has a high affinity for hyaluronic acid (HA) binding and is a desirable receptor for active targeting based on its overexpression in cancer cells compared with normal body cells. The nanocarrier affinity can be increased by conjugating drug-loaded carriers with HA, allowing enhanced cancer cell uptake via the HA-CD44 receptor-mediated endocytosis pathway. In this review, we discuss recent advances in HA-based nanocarriers and micelles for cancer therapy. In vitro and in vivo experiments have repeatedly indicated HA-based nanocarriers to be a target-specific drug and gene delivery platform with great promise for future applications in clinical cancer therapy. Hyaluronic acid (HA) has potential as a unique targeting ligand for treating multiple types of tumor overexperssing cluster-determinant 44 (CD44) receptors, including stem-like cancer cells (SLCC). Here, we discuss the innovative approaches of HA-decorated nanocarriers developed by researchers for delivering drugs and genes to cancer cells.",
author = "Wickens, {Jennifer M.} and Alsaab, {Hashem O.} and Prashant Kesharwani and Ketki Bhise and {Mohd Amin}, {Mohd Cairul Iqbal} and Tekade, {Rakesh Kumar} and Umesh Gupta and Iyer, {Arun K.}",
year = "2016",
doi = "10.1016/j.drudis.2016.12.009",
language = "English",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy

AU - Wickens, Jennifer M.

AU - Alsaab, Hashem O.

AU - Kesharwani, Prashant

AU - Bhise, Ketki

AU - Mohd Amin, Mohd Cairul Iqbal

AU - Tekade, Rakesh Kumar

AU - Gupta, Umesh

AU - Iyer, Arun K.

PY - 2016

Y1 - 2016

N2 - The cluster-determinant 44 (CD44) receptor has a high affinity for hyaluronic acid (HA) binding and is a desirable receptor for active targeting based on its overexpression in cancer cells compared with normal body cells. The nanocarrier affinity can be increased by conjugating drug-loaded carriers with HA, allowing enhanced cancer cell uptake via the HA-CD44 receptor-mediated endocytosis pathway. In this review, we discuss recent advances in HA-based nanocarriers and micelles for cancer therapy. In vitro and in vivo experiments have repeatedly indicated HA-based nanocarriers to be a target-specific drug and gene delivery platform with great promise for future applications in clinical cancer therapy. Hyaluronic acid (HA) has potential as a unique targeting ligand for treating multiple types of tumor overexperssing cluster-determinant 44 (CD44) receptors, including stem-like cancer cells (SLCC). Here, we discuss the innovative approaches of HA-decorated nanocarriers developed by researchers for delivering drugs and genes to cancer cells.

AB - The cluster-determinant 44 (CD44) receptor has a high affinity for hyaluronic acid (HA) binding and is a desirable receptor for active targeting based on its overexpression in cancer cells compared with normal body cells. The nanocarrier affinity can be increased by conjugating drug-loaded carriers with HA, allowing enhanced cancer cell uptake via the HA-CD44 receptor-mediated endocytosis pathway. In this review, we discuss recent advances in HA-based nanocarriers and micelles for cancer therapy. In vitro and in vivo experiments have repeatedly indicated HA-based nanocarriers to be a target-specific drug and gene delivery platform with great promise for future applications in clinical cancer therapy. Hyaluronic acid (HA) has potential as a unique targeting ligand for treating multiple types of tumor overexperssing cluster-determinant 44 (CD44) receptors, including stem-like cancer cells (SLCC). Here, we discuss the innovative approaches of HA-decorated nanocarriers developed by researchers for delivering drugs and genes to cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=85009516161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009516161&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2016.12.009

DO - 10.1016/j.drudis.2016.12.009

M3 - Article

C2 - 28017836

AN - SCOPUS:85009516161

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

ER -